


Summary
The regulation of similar biotherapeutic products varies widely among the different Latin American countries. While some of them are yet to introduce their own regulation, others — like Brazil and Mexico — have opened ways to cheaper, complex and safe biological treatment for patients. However, many things need improving and a lot of experience is still necessary to develop a mature LATAM Biosimilars Market.
Biosimilars Latam – Brazil 2019 is a unique and effective meeting point to share the information and experience Latin America’s Pharmaceutical Industry needs to develop a dynamic and thriving biosimilars market.
Join us in Brazil and trigger a quantum leap in Latin American Healthcare!
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
From these areas:
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Speaker Board

Augusto H. Geraldi
BD, Brazil
BU Leader - Latam and Brazil - Pharmaceutical Systems
BU Leader - Latam and Brazil - Pharmaceutical Systems

Alison Bascou
BD, France
Sr. Regulatory Director
Sr. Regulatory Director

Carlos Eduardo Sverdloff
Synova, Brazil
Director
Director

Vanda Magalhães, R&D Manager at Bionovis, Brazil
Bionovis, Brazil
R&D Manager
R&D Manager

Brian J. Wendelburg
Sartorius Stedim Biotech , USA
Application Specialist, Americas (BioOutsource & Cellca)
Application Specialist, Americas (BioOutsource & Cellca)

Mauricio Rubio
Suanfarma, Colombia
Country Manager Colombia
Country Manager Colombia

Debora Rodrigues
Cristália, Brazil
Clinical Research Manager
Clinical Research Manager

Adilson Montaneira
Former Pfizer, Brazil
Business Unit Director - Biosimilar
Business Unit Director - Biosimilar

Felipe Rodriguez-Davison
Orphan Drugs Consulting, Mexico
Scientific Affairs Lead
Scientific Affairs Lead

Tammy Boggiano Ayo
Molecular Immunology Center (CIM), Cuba
Process Development Director at INIM
Process Development Director at INIM

Renato Porto
ANVISA, Brazil
Director of Regulations
Director of Regulations

Daniela Cerqueira
ANVISA, Brazil
General Manager of Medicines and Biological Products
General Manager of Medicines and Biological Products

Francisco Kuri Breña
AMELAF, Mexico
Biotechnology Coordinator
Biotechnology Coordinator

Nestor Lago
Gemabiotech, Argentina
Medical Director
Medical Director

Pedro Aranha
Sandoz, Brazil
Strategic Planning Manager
Strategic Planning Manager

Rodrigo Silvestre
Alfob, Brazil
Economist
Economist

Marcelo Nogueira
Novartis, Brazil
Global Director, Head of Ethics, Risk and Compliance Operations
Global Director, Head of Ethics, Risk and Compliance Operations

Eduardo Cioppi
mAbxience, Spain
Global Sales Director
Global Sales Director

Lori Daane
bioMérieux, USA
Director of Scientific Affairs
Director of Scientific Affairs

Thiago Mares Guia
Bionovis, Brazil
Executive Vice President
Executive Vice President
Development of Biosimilars: Influence of process variables on critical attributes related to clinical efficacy
Best Practice: How to get move a biosimilar in an emerging market?
Challenges and Opportunities for the Legal and Compliance Environment of Biosimilars in Latin America.
Panel: The Latam Industry Approach
Panel: Evaluating the 5+ Years of PDP Project
“The State of Art in Biosimilar Interchangeability” - Things we need to consider
Panel with leaders: What the Future of Biosimilars Is?

Sponsors
Photo Gallery
